Digoxin-cyclosporin A interaction

Modulation of the multidrug transporter P-glycoprotein in the kidney

N. Okamura, M. Hirai, Yusuke Tanigawara, K. Tanaka, M. Yasuhara, K. Ueda, T. Komano, R. Hori

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

The mechanism of a renal tubular digoxin-cyclosporin A interaction was elucidated using a kidney epithelial cell line and the isolated perfused rat kidney. The cells expressed an excess amount of human P-glycoprotein on the apical membranes by transfection with MDR1 cDNA. Cyclosporin A inhibited the trans-epithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 μM cyclosporin A, respectively. Cyclosporin A also reduced the renal tubular secretion of digoxin by the kidney. The ratio of fractional excretion/filtration fraction for digoxin was 2.88 ± 0.71 (mean ± S.D.) in the control, and this was decreased to 1.21 ± 0.09 and 1.05 ± 0.13 in the presence of 1 and 5 μM cyclosporin A, respectively. Because no signs of acute nephrotoxicity were observed, a direct effect of cyclosporin A accounted for the reduced secretion. On the other hand, digoxin did not affect cyclosporin A transport by P-glycoprotein. These findings indicate that serum concentrations of digoxin in patients should be carefully monitored when administered concurrently with cyclosporin A. The present transepithelial transport system using the transfectant cells is a simple and useful screening system for predicting drug interactions that can occur in a clinical situation.

Original languageEnglish
Pages (from-to)1614-1619
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume266
Issue number3
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Digoxin
P-Glycoprotein
Cyclosporine
Kidney
Drug Interactions
Transfection
Complementary DNA
Epithelial Cells
Cell Line
Membranes
Serum

ASJC Scopus subject areas

  • Pharmacology

Cite this

Digoxin-cyclosporin A interaction : Modulation of the multidrug transporter P-glycoprotein in the kidney. / Okamura, N.; Hirai, M.; Tanigawara, Yusuke; Tanaka, K.; Yasuhara, M.; Ueda, K.; Komano, T.; Hori, R.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 266, No. 3, 1993, p. 1614-1619.

Research output: Contribution to journalArticle

Okamura, N, Hirai, M, Tanigawara, Y, Tanaka, K, Yasuhara, M, Ueda, K, Komano, T & Hori, R 1993, 'Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney', Journal of Pharmacology and Experimental Therapeutics, vol. 266, no. 3, pp. 1614-1619.
Okamura, N. ; Hirai, M. ; Tanigawara, Yusuke ; Tanaka, K. ; Yasuhara, M. ; Ueda, K. ; Komano, T. ; Hori, R. / Digoxin-cyclosporin A interaction : Modulation of the multidrug transporter P-glycoprotein in the kidney. In: Journal of Pharmacology and Experimental Therapeutics. 1993 ; Vol. 266, No. 3. pp. 1614-1619.
@article{5af78bff803b442db5bd12fe9196f28b,
title = "Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney",
abstract = "The mechanism of a renal tubular digoxin-cyclosporin A interaction was elucidated using a kidney epithelial cell line and the isolated perfused rat kidney. The cells expressed an excess amount of human P-glycoprotein on the apical membranes by transfection with MDR1 cDNA. Cyclosporin A inhibited the trans-epithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 μM cyclosporin A, respectively. Cyclosporin A also reduced the renal tubular secretion of digoxin by the kidney. The ratio of fractional excretion/filtration fraction for digoxin was 2.88 ± 0.71 (mean ± S.D.) in the control, and this was decreased to 1.21 ± 0.09 and 1.05 ± 0.13 in the presence of 1 and 5 μM cyclosporin A, respectively. Because no signs of acute nephrotoxicity were observed, a direct effect of cyclosporin A accounted for the reduced secretion. On the other hand, digoxin did not affect cyclosporin A transport by P-glycoprotein. These findings indicate that serum concentrations of digoxin in patients should be carefully monitored when administered concurrently with cyclosporin A. The present transepithelial transport system using the transfectant cells is a simple and useful screening system for predicting drug interactions that can occur in a clinical situation.",
author = "N. Okamura and M. Hirai and Yusuke Tanigawara and K. Tanaka and M. Yasuhara and K. Ueda and T. Komano and R. Hori",
year = "1993",
language = "English",
volume = "266",
pages = "1614--1619",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Digoxin-cyclosporin A interaction

T2 - Modulation of the multidrug transporter P-glycoprotein in the kidney

AU - Okamura, N.

AU - Hirai, M.

AU - Tanigawara, Yusuke

AU - Tanaka, K.

AU - Yasuhara, M.

AU - Ueda, K.

AU - Komano, T.

AU - Hori, R.

PY - 1993

Y1 - 1993

N2 - The mechanism of a renal tubular digoxin-cyclosporin A interaction was elucidated using a kidney epithelial cell line and the isolated perfused rat kidney. The cells expressed an excess amount of human P-glycoprotein on the apical membranes by transfection with MDR1 cDNA. Cyclosporin A inhibited the trans-epithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 μM cyclosporin A, respectively. Cyclosporin A also reduced the renal tubular secretion of digoxin by the kidney. The ratio of fractional excretion/filtration fraction for digoxin was 2.88 ± 0.71 (mean ± S.D.) in the control, and this was decreased to 1.21 ± 0.09 and 1.05 ± 0.13 in the presence of 1 and 5 μM cyclosporin A, respectively. Because no signs of acute nephrotoxicity were observed, a direct effect of cyclosporin A accounted for the reduced secretion. On the other hand, digoxin did not affect cyclosporin A transport by P-glycoprotein. These findings indicate that serum concentrations of digoxin in patients should be carefully monitored when administered concurrently with cyclosporin A. The present transepithelial transport system using the transfectant cells is a simple and useful screening system for predicting drug interactions that can occur in a clinical situation.

AB - The mechanism of a renal tubular digoxin-cyclosporin A interaction was elucidated using a kidney epithelial cell line and the isolated perfused rat kidney. The cells expressed an excess amount of human P-glycoprotein on the apical membranes by transfection with MDR1 cDNA. Cyclosporin A inhibited the trans-epithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 μM cyclosporin A, respectively. Cyclosporin A also reduced the renal tubular secretion of digoxin by the kidney. The ratio of fractional excretion/filtration fraction for digoxin was 2.88 ± 0.71 (mean ± S.D.) in the control, and this was decreased to 1.21 ± 0.09 and 1.05 ± 0.13 in the presence of 1 and 5 μM cyclosporin A, respectively. Because no signs of acute nephrotoxicity were observed, a direct effect of cyclosporin A accounted for the reduced secretion. On the other hand, digoxin did not affect cyclosporin A transport by P-glycoprotein. These findings indicate that serum concentrations of digoxin in patients should be carefully monitored when administered concurrently with cyclosporin A. The present transepithelial transport system using the transfectant cells is a simple and useful screening system for predicting drug interactions that can occur in a clinical situation.

UR - http://www.scopus.com/inward/record.url?scp=0027856015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027856015&partnerID=8YFLogxK

M3 - Article

VL - 266

SP - 1614

EP - 1619

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -